Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension
about
Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosisPlasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adultsDimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginineRoles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in ratsAsymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis.Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine.Asymmetric dimethylarginine in angiotensin II-induced hypertensionRestoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation.The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular DiseaseRestoration of asymmetric dimethylarginine-nitric oxide balance to prevent the development of hypertension.Role of cardiovascular imaging in systemic autoimmune diseasesImplications for the role of endogenous nitric oxide inhibitors in hemodialysis hypotension.A systematic review of metabolite profiling in gestational diabetes mellitus.Dimethylarginine dimethylaminohydrolase1 is an organ-specific mediator of end organ damage in a murine model of hypertensionAmino acids, arginase and nitric oxide in vascular health.Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and AktVascular Nitric Oxide: Formation and Function.Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level.The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function.Insulin resistance, hypertension, and coronary heart disease.Diabetes and alpha lipoic Acid.Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitusLong-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension.Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplastyAsymmetrical dimethylarginine and severity of erectile dysfunction and their impact on cardiovascular events in patients with acute coronary syndromeoxLDL downregulates the dendritic cell homing factors CCR7 and CCL21L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure.Plasma ADMA associates with all-cause mortality in renal transplant recipients.Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.Mechanism of cellular oxidation stress induced by asymmetric dimethylarginine.Nitric oxide and sympathetic nerve activity in the control of blood pressure.Targeting endothelial dysfunction in hypertensive subjects.Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality.ADMA: its role in vascular disease.Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.Associations between endogenous dimethylarginines and renal function in healthy children and adolescents.Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.Arginine, arginine analogs and nitric oxide production in chronic kidney disease.Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs
P2860
Q26795604-A19F4C72-5A66-4830-B8B1-9C7B73EACC46Q28247348-FA19BDDE-E80C-4F57-AFD6-CC7E13594978Q28506246-90AD05A0-C464-47A0-9211-D8B2A86698E7Q28578942-43FEF3D5-C5D3-40DF-89C9-89D596DCCD8BQ31001162-4930B53A-FD33-4A89-A8E0-64B0ACCCA396Q33582151-832E3FE3-6B44-4AF5-B496-8F4DF94C81A0Q33728163-82DF6F4A-4431-43A1-8267-E87745F0DC4BQ33887449-D6BFB653-A47D-4334-8B24-62508FB25759Q33940891-337A5C06-D1B6-4869-80C0-0E5765695CFEQ34072296-0EEEFF13-39D8-4297-A4D7-1BE246C2A106Q34390705-CF0A83EE-38C6-4886-B909-537E750796DAQ34430050-ED238664-464E-4A7C-9318-0F89091CF35FQ34458995-3D1A558E-8C8C-45FF-A533-6F983B07BB42Q34460993-25190C40-7208-4C0D-871F-C34EA32F4E98Q34489450-A3731D1E-D057-40A7-9FC3-C24A01E1110EQ34721519-C41C1612-19A7-4C61-81BA-DEE7F4A6F822Q34973956-290C6F4A-2A49-4CDB-9350-1E0342FAD715Q35044177-F480D231-E5BB-4103-82AA-44722CFEEF0AQ35055194-473BF4F6-52F8-4854-8A6A-A070E8FB5604Q35206312-816F69F7-C447-406E-A058-3F3F896059CFQ35564911-024CFD3C-4F20-416E-89D0-3D072F4611CFQ35622245-5BF1B5DD-9366-4F08-8B05-B327C5C9263BQ35642062-8490ED0A-B1BF-4B6F-A75D-009C046EF648Q35674171-3FB24AA6-2AF5-4FF3-A992-63F027BD1F40Q35762008-B542FBAB-443D-4000-846A-F43E543A7899Q35954820-FAD1AB5E-91FD-41E4-9ECA-60D9CB232408Q35961528-779D4CC4-EF52-455F-9450-87083925CA6CQ35995894-D8DDA4DC-D0E7-435C-B003-815B81A33898Q36018553-A17C9017-DE82-4553-8C49-4CD70F6A5A8FQ36097000-0A4CD05E-F108-4BE8-96FC-FC97F9B4C9DAQ36107879-5DF09CE6-57ED-430E-B3FC-0CD58CC85243Q36216260-BB645375-B7E5-4309-81F7-0D747D3C2610Q36273352-C8E41FD0-3EF9-4E5F-801B-D021431DD741Q36380994-0D9A80B6-239B-4883-BCD4-78F9E52275FDQ36381000-BA92C812-3A32-4C50-901E-E8D624FC6B8BQ36381003-B1D718B3-5A50-4E28-9DAA-FF148BCBB3FFQ36432652-FD9B737C-28A3-4615-8938-AF5DBD28D880Q36438224-1A1B8A22-06EF-4B96-8593-098EEB1D7EB3Q36577145-4A9E3789-53F9-431F-A99C-82409A054EA1Q36622844-8429F1BA-F58B-4003-A3BF-C03F9D986894
P2860
Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Reduced urinary excretion of n ...... en with essential hypertension
@ast
Reduced urinary excretion of n ...... en with essential hypertension
@en
Reduced urinary excretion of n ...... en with essential hypertension
@nl
type
label
Reduced urinary excretion of n ...... en with essential hypertension
@ast
Reduced urinary excretion of n ...... en with essential hypertension
@en
Reduced urinary excretion of n ...... en with essential hypertension
@nl
prefLabel
Reduced urinary excretion of n ...... en with essential hypertension
@ast
Reduced urinary excretion of n ...... en with essential hypertension
@en
Reduced urinary excretion of n ...... en with essential hypertension
@nl
P2093
P1476
Reduced urinary excretion of n ...... en with essential hypertension
@en
P2093
A Surdacki
J C Froelich
J S Dubiel
J Sandmann
O Kruszelnicka-Kwiatkowska
R H Boeger
S M Bode-Boeger
P356
10.1097/00005344-199904000-00020
P407
P577
1999-04-01T00:00:00Z